X-Energy, which develops small modular reactors and produces nuclear fuel, raised $1.0 billion by offering 44.3 million shares at $23, above the $16 to $19 range. The company offered 1.4 million more shares than anticipated. ARK Investment Management had...read more
CH4 Natural Solutions Acquisition, a blank check company backed by Impact Ag, Riverstone's David Leuschen, and Overview Capital's Lauren Singer, lowered the proposed deal size for its upcoming IPO on Friday. The New York, NY-based company now plans to raise...read more
Avalyn Pharma, a Phase 2 biotech developing inhaled medicines for rare respiratory diseases, announced terms for its IPO on Thursday. The Boston, MA-based company plans to raise $201 million by offering 11.8 million shares at a price range of $16 to $18. ...read more
Small modular reactor developer X-Energy prices upsized IPO at $23, above the range
X-Energy, which develops small modular reactors and produces nuclear fuel, raised $1.0 billion by offering 44.3 million shares at $23, above the $16 to $19 range. The company offered 1.4 million more shares than anticipated. ARK Investment Management had...read more
SPAC CH4 Natural Solutions Acquisition decreases units offered by 33% ahead of $200 million IPO
CH4 Natural Solutions Acquisition, a blank check company backed by Impact Ag, Riverstone's David Leuschen, and Overview Capital's Lauren Singer, lowered the proposed deal size for its upcoming IPO on Friday. The New York, NY-based company now plans to raise...read more
Pulmonary fibrosis biotech Avalyn Pharma sets terms for $201 million IPO
Avalyn Pharma, a Phase 2 biotech developing inhaled medicines for rare respiratory diseases, announced terms for its IPO on Thursday. The Boston, MA-based company plans to raise $201 million by offering 11.8 million shares at a price range of $16 to $18. ...read more